BIOAVAILABILITY ENHANCEMENT OF POORLY SOLUBLE RALOXIFENE BY DESIGNING INCLUSION COMPLEX WITH Î²â€“CYCLODEXTRIN
Objective: Raloxifene hydrochloride (RLX) is widely used in the treatment of osteoporosis, but due to its extensive first pass metabolism bioavailability of RLX is remaining only 2%. In addition of that being from BCS class II, RLX has poor water solubility. Therefore the objective of present research work was to enhance solubility and dissolution rate of RLX by formulating inclusion complex with Î² cyclodextrin (Î²-CD) as a carrier.
Methods: Inclusion complex was prepared by various methods like physical mixture, co-precipitation method and kneading method using different drug to carrier ratios (1:1, 1:2 and 1:3).
Results: Inclusion complex prepared with co-precipitation method had shown 5.5 fold improvements in water solubility and significant increment in dissolution rate when compared with plain RLX. Optimized formulation was characterized by Fourier transform infrared spectroscopy, Differential scanning calorimetry, X-ray diffraction and Scanning electron microscopy studies for their compatibility, thermal analysis, crystallinity and surface morphology determination, respectively. Results of DSC and XRD study suggested the conversion of RLX from crystalline form to amorphous form. Stability studies showed stable formulation up to the period of 6 months. In vivo pharmacokinetic study was also conducted in wistar rats for optimized drug loaded inclusion complex that showed nearby two fold increments in drug bioavailability compared to plain drug suspension.
Conclusion: From these studies, it can be concluded that solubility and dissolution rate of poorly soluble raloxifene could be remarkably increased by formulating into the inclusion complex with Î²-CD which results in significant improvement in bioavailability of poorly soluble RLX.
2. Recker RR, Kendler D, Recknor CP, Rooney TW, Michael Lewiecki E, Utian WH, et al. Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass. Bone 2007;40:843â€“51.
3. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637â€“65.
4. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609â€“17.
5. Riggs BL, Hartmann LC. Selective estrogen-receptor modulatorsâ€”mechanisms of action and application to clinical practice. N Engl J Med 2003;348:618â€“29.
6. Patil PH, Belgamwar VS, Patil PR, Surana SJ. Solubility enhancement of raloxifene using inclusion complexes and cogrinding method. J Pharm 2013: doi.org/10.1155/2013/527380. [Article in Press].
7. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS Pharm Sci Tech 2005;6(2):1-29.
8. Sapkal NP, Kilor VA, Bhusari KP, Daud AS. Evaluation of some methods for preparing gliclazide-Î²-cyclodextrin inclusion complexes. Trop J Pharm Res 2007;6(4):833-40.
9. Sreenivasa RK, Iqbal MM, Shirse P. Preparation and evaluation of cyclodextrin inclusion complexs of water insoluble drug-Glimipiride. Int J Res Pharm Biol Sci 2012;3(1):428-34.
10. Ghodke DS, Nakhat PD, Yeole PG, Naikwade NS, Magdum CS, Shah RR. Preparation and characterization of domperidone inclusion complexes with cyclodextrin: Influence of preparation method. Iran J Pharm Res 2009;8(3):145-51.
11. Tomoko O, Hiraku O, Machida Y. Novel preparation of enteric-coated chitosan-prednisolone conjugates microspheres and in vitro evaluation of their potential as a colonic delivery system. Eur J Pharm Biopharm 2008;68:260â€“6.
12. Patel HM, Suhagia BN, Shah SA, Rathod IS, Parmar VK. Preparation and characterization of etoricoxib beta cyclodextrin complexes prepared by the kneading method. Acta Pharm 2007;57:351-9.
13. Pandit V, Gorantla R, Devi K, Pai RS, Sarasija S. Preparation and characterization of Pioglitazone cyclodextrin inclusion complexes. J Young Pharm 2011;3:267-74.
14. Kushwaha AK, Vuddanda PR, Karunanidhi P, Singh SK, Singh S. Development and evaluation of solid lipid nanoparticles of Raloxifene hydrochloride for enhanced bioavailability. Biochem Res Int 2012: doi.org/10.1155/2013/584549. [Article in Press].
15. Sahoo SK, Mallick AA, Barik BB, Senapati CP. Formulation of Eudragit Microspheres of stavudine. Trop J Pharm Res 2005;4(1):369-75.
16. Ashvini U, Kavitha K, Mehaboob Y. Design and evaluation of ketoprofen loaded albumin microspheres. Pharma Sci Monit 2011;2(3):189-203.
17. Jat RC, Jain S, Dubey S, Jain V, Bhardwaj S, Jain A. Preparation and evaluation of colon targeting microspheres. J Pharm Res 2010;3(3):596-9.
18. Stability testing of new drug substances and products Q1A (R2). ICH harmonised tripartite guideline. Current step 4 version, February, 2003. Available from http://www. ich. org/fileadmin/ Public_Web_Site/ICH_Products/Guidelines/Quality/Q1A_R2/Step4/Q1A_R2__Guideline. pdf [Last accessed on 10 Apr 2015]
19. Yang ZY, Zhang ZF, He XB, Zhao GY, Zhang YQ. Validation of a novel HPLC method for the determination of raloxifene and its pharmacokinetics in rat plasma. Chromatographia 2007; 65:197-201.
20. Tran TH, Poudel BK, Marasini N, Chi SC, Choi HG, Yong CS, et al. Preparation and evaluation of raloxifene loaded solid dispersion nanoparticle by spray drying technique without an organic solvent. Int J Pharm 2013;443:50-7.
21. Ravi PR, Aditya N, Kathuria H, Malekar S, Vats R. Lipid nanoparticles for oral delivery of raloxifene: optimization, stability, In vivo evaluation and uptake mechanism. Eur J Pharm Biopharm 2014;87:114-24.
22. Jha RK, Tiwari S, Mishra B. Bioadhesive microspheres for bioavailability enhancement of raloxifene hydrochloride: formulation and pharmacokinetics evaluation. AAPS Pharm Sci Tech 2011;12(2):650-7.